人工肝支持系统相关血管迷走神经反应的特征。
Characterization of an Artificial Liver Support System-Related Vasovagal Reaction.
机构信息
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
出版信息
Biomed Res Int. 2020 Jul 13;2020:6313480. doi: 10.1155/2020/6313480. eCollection 2020.
OBJECTIVE
An artificial liver support system (ALSS) is an effective therapy for patients with severe liver injury. A vasovagal reaction (VVR) is a common complication in various treatment settings but has not been reported previously in ALSS.
METHODS
This study retrospectively evaluated patients who suffered an ALSS-related VRR between January 2018 and June 2019. We collected data from VVR episodes including onset time, duration, changes in heart rate (HR) and blood pressure (BP), and drug treatment.
RESULTS
Among 637 patients who underwent ALSS treatment, 18 were included in the study. The incidence of VVR was approximately 2.82%. These patients were characterized by a rapid decrease in BP or HR with associated symptoms such as chest distress, nausea, and vomiting. The majority of patients (78%) suffered a VVR during their first ALSS treatment. Sixteen patients (89%) had associated symptoms after treatment began. Sixteen patients (89%) received human albumin or Ringer's solution. Atropine was used in 11 patients (61%). The symptoms were relieved within 20 min in 15 patients and over 20 min in 3 patients.
CONCLUSIONS
A VVR is a rare complication in patients with severe liver injury undergoing ALSS treatment. Low BP and HR are the main characteristics of a VVR.
目的
人工肝支持系统（ALSS）是治疗严重肝损伤患者的有效疗法。血管迷走性反应（VVR）是各种治疗环境中的常见并发症，但以前在 ALSS 中并未报告过。
方法
本研究回顾性评估了 2018 年 1 月至 2019 年 6 月期间发生与 ALSS 相关的 VRR 的患者。我们收集了 VVR 发作的相关数据，包括发作时间、持续时间、心率（HR）和血压（BP）的变化以及药物治疗情况。
结果
在 637 例接受 ALSS 治疗的患者中，有 18 例纳入研究。VVR 的发生率约为 2.82%。这些患者的特征是血压或 HR 迅速下降，伴有胸痛、恶心和呕吐等相关症状。大多数患者（78%）在首次 ALSS 治疗时发生 VVR。开始治疗后，有 16 名患者（89%）出现相关症状。16 名患者（89%）接受了人血白蛋白或林格氏液。11 名患者（61%）使用了阿托品。15 名患者的症状在 20 分钟内缓解，3 名患者的症状缓解时间超过 20 分钟。
结论
VVR 是严重肝损伤患者接受 ALSS 治疗时罕见的并发症。低血压和低心率是 VVR 的主要特征。
Zotero 插件